PATHOMORPHOGENESIS OF LIVER STEATOSIS IN PATIENTS WITH OPIOID DEPENDENCE
Abstract
Background. One of the significant factors in the progression of fibrotic changes in the liver is hepatocyte steatosis, that persists in drug addicted patients even after the elimination of the hepatitis C virus and cessation of drug use. Analysis of the pathomorphogenesis of hepatic steatosis in opioid dependence (OZ) will make it possible to assess the factors that affect ultrastructural changes in hepatocytes and the processes of lipid granule (LH) degradation. Objective. Assessment of ultrastructural changes in LH in the liver tissue of patients with OZ. Material and methods. Histological preparations of liver tissue from 20 patients with OZ aged 21 to 40 years (18 men and 2 women) with different duration of OZ and opioid tolerance. Results. There was established the following dependence of ultrastructural changes in the liver in patients with different duration of OZ and opioid tolerance. The most pronounced changes were noted in the group of patients with prolonged (more than 6 years) opioid intoxication and high tolerance to opioids in the liver tissue, in whom, along with severe steatosis, there were more significant violations of the mechanisms of LH degradation, destruction of cristae in mitochondria, a decrease in the number of lipophagosomes and PH with signs of superficial degradation than in the group of patients with OZ duration up to 6 years, as well as with moderate and high opioid tolerance. Conclusions. Ultrastructural changes in hepatocytes in the form of progression of steatosis in the centrilobular and periportal zones, a decrease in the activity of LH degradation, gross morphological changes in mitochondria, a decrease in the activity of surface LH degradation depend on the activity and duration of opioid dependence and are more pronounced with long-term (more than 6 years) highly progressive opioid dependence.References
Coffa D, Snyder H. Opioid Use Disorder: Medical Treatment Options. Am. Fam. Physician. 2019;100(7):416-425.
Sosin IK, Chuev JuF. Narkologija. Kharkov: Kollegium; 2005. 800 p. (Russian).
Deputy NP, Lowry R, Clayton HB, Demissie Z, Bohm MK, Conklin S. Initiation of nonmedical use of prescription opioids among high school students. Subst. Abus. 2021;Mar 8:1-6. https://doi.org/10.1080/08897077.2021.1892013.
Zibbell JE, Asher AK, Patel RC, Kupronis B, Iqbal K, Ward JW, Holtzman D. Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014. Am. J. Public Health. 2018;108(2):175-181. https://doi.org/10.2105/AJPH.2017.304132.
Holtzman D, Asher AK, Schillie S. The Changing Epidemiology of Hepatitis C Virus Infection in the United States During the Years 2010 to 2018. Am. J. Public Health. 2021;111(5):949-955. https://doi.org/10.2105/AJPH.2020.306149.
Springer SA, Rio CD. Co-located Opioid Use Disorder and Hepatitis C Virus Treatment Is Not Only Right, But It Is Also the Smart Thing To Do as It Improves Outcomes! Clin. Infect. Dis. 2020;71(7):1723-1725. https://doi.org/10.1093/cid/ciaa111.
Caines A, Selim R, Salgia R. The Changing Global Epidemiology of Hepatocellular Carcinoma. Clin. Liver Dis. 2020;24(4):535-547. https://doi.org/10.1016/j.cld.2020.06.001.
Cunningham EB, Hajarizadeh B, Amin J, Hellard M, Bruneau J, Feld JJ, Cooper C, Powis J, Litwin AH, Marks P, Dalgard O, Conway B, Moriggia A, Stedman C, Read P, Bruggmann P, Lacombe K, Dunlop A, Applegate TL, Matthews GV, Fraser C, Dore GJ, Grebely J. Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs. Clin. Infect. Dis. 2021;72(8):1392-1400. https://doi.org/10.1093/cid/ciaa253.
Heo M, Pericot-Valverde I, Rennert L, Akiyama MJ, Norton BL, Gormley M, Agyemang L, Arnsten JH, Litwin AH. Hepatitis C virus DAA treatment adherence patterns and SVR among people who inject drugs treated in opioid agonist therapy programs. Clin. Infect. Dis. 2021;ciab334. https://doi.org/10.1093/cid/ciab334.
Moon AM, Watkins SE, Lok AS, Firpi-Morell RJ, Trinh HN, Kupec JT, Schoen C, Neuschwander-Tetri BA, Barritt AS. Opioid Use is More Common in Non-Alcoholic Fatty Liver Disease Patients with Cirrhosis, Higher Body Mass Index and Psychiatric Disease. Dig. Dis. 2021;39(3):247-257. https://doi.org/10.1159/000511074.
Mauss S, Buendgens L, Christensen S, Ingiliz P, Berger F, Hüppe D, Simon KG, Lutz T, Schewe K, Boesecke C, Tacke F. Risk factors for remaining liver injury in patients with virological elimination of chronic hepatitis C. Z. Gastroenterol. 2019;57(2):139-147. https://doi.org/10.1055/a-0752-0514.
Pierre V, Johnston CK, Ferslew BC, Brouwer Klr, Gonzalez D. CPT Population Pharmacokinetics of Morphine in Patients with Nonalcoholic Steatohepatitis (NASH) and Healthy Adults. Pharmacometrics Syst. Pharmacol. 2017;6(5):331-339. https://doi.org/10.1002/psp4.12185.
Bljuger AF, Zalcmane VK, Kartashova OJa. Ultrastrukturnaja patologija pecheni: Jelektoronno-mikroskopicheskij atlas. Riga: Zinantne; 1989. 319 p. (Russian).
Sekamova SM, Serov VV, Tanaschuk EL, Popova IV, Yusov SP. Jelektronno-mikroskopicheskoe issledovanie pecheni pri hronicheskom virusnom gepatite S v sochetanii s alkogolnoj boleznju pecheni [Electron-microscopic study of the liver in chronic viral hepatitis c combined with alcoholic liver disease]. Arhiv patologii [Archive of Pathology]. 1998;60(5):52-58. (Russian).
1.png)
